Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fusion-VAC-XS15 |
Synonyms | |
Therapy Description |
Fusion-VAC-XS15 is a personalized vaccine comprising peptides derived from the DNAJB1-PRKACA fusion protein, which potentially enhances antitumor immune response (PMID: 36302754). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fusion-VAC-XS15 | Fusion-VAC-XS15 is a personalized vaccine comprising peptides derived from the DNAJB1-PRKACA fusion protein, which potentially enhances antitumor immune response (PMID: 36302754). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05937295 | Phase I | Fusion-VAC-XS15 Atezolizumab + Fusion-VAC-XS15 | FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition (FusionVAC22) | Recruiting | DEU | 0 |